Evidence map›Paper›PMID 22735487›Full record

ArticleExperimental neurology2012

Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS.

Bing Liao, Weihua Zhao, David R Beers, Jenny S Henkel, Stanley H Appel

Registry-linked trialAbstract read
In one paragraph

Article in Experimental neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02325375 (Inflammation in Amyotrophic Lateral Sclerosis - a Study of Soluble Cluster of Differentiation 163 in the Cerebrospinal Fluid), which is not on this map. Cited by 260 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
260citing papers in PubMed, 2 pooled it
19.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02325375 completednot on this mapstarted 2014, after this paper: background citation

Inflammation in Amyotrophic Lateral Sclerosis - a Study of Soluble Cluster of Differentiation 163 in the Cerebrospinal Fluid

TypeobservationalSponsorUniversity of AarhusRan2014 to 2016Enrolled20ConditionsAmyotrophic Lateral SclerosisArmslumbar puncture for spinal fluid and blood sample
3 · Its place in the literature

Who cites it

260 citing papers in PubMed, 2 syntheses or guidelines pooled it, 417 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

200 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Bing LiaoDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, China. biliao@utmb.edu
Weihua Zhao
David R Beers
Jenny S Henkel
Stanley H Appel
Houston Methodist · USXiangya Hospital Central South University · CN

Funding

Using CD4+ T cells as a candidate therapy to slow disease progression in ALSR21NS067153 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI APPEL, STANLEY H. · 2010 to 2011
$424k
CD4+CD25+ Treg cells regulate microglia and provide neuroprotection in ALSR03NS070050 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI ZHAO, WEIHUA · 2010 to 2011
$152k
NINDS NIH HHS NS067153NINDS NIH HHS NS70050NINDS NIH HHS R03 NS070050NINDS NIH HHS R21 NS067153
6 · The paper itself

Abstract

Neuroinflammation is a prominent pathological feature in the spinal cords of patients with amyotrophic lateral sclerosis (ALS), as well as in transgenic mouse models of inherited ALS, and is characterized by activated microglia. Earlier studies showed that activated microglia play important roles in both motoneuron protection and injury. More recent studies investigating the pathoprogression of disease in ALS mice have demonstrated that the in vivo activation states of microglia, including their anti- versus pro-inflammatory responses, are best characterized as a continuum between two extreme activation states which are represented as a neuroprotective M2 (alternatively-activated) phenotypic state or an injurious/toxic M1 (classically-activated) state; a more complete understanding and determination the temporal transformation of microglia activation states in the ALS disease pathoprogression is therefore warranted. In the current study, we demonstrated a phenotypic and functional transformation of adult ALS mice microglia that overexpress mutant superoxide dismutase (mSOD1). mSOD1 microglia isolated from ALS mice at disease onset expressed higher levels of Ym1, CD163 and BDNF (markers of M2) mRNA and lower levels of Nox2 (a marker of M1) mRNA compared with mSOD1 microglia isolated from ALS mice at end-stage disease. More importantly, when co-cultured with motoneurons, these mSOD1 M2 microglia were neuroprotective and enhanced motoneuron survival than similarly co-cultured mSOD1 M1 microglia; end-stage mSOD1 M1 microglia were toxic to motoneurons. Our study documents that adult microglia isolated from ALS mice at disease onset have an M2 phenotype and protect motoneurons whereas microglia isolated from end-stage disease ALS mice have adopted an M1 phenotype and are neurotoxic supporting the dual phenotypes of microglia and their transformation during disease pathoprogression in these mice. Thus, harnessing the neuroprotective potential of microglia may provide novel avenues for ALS therapies.

Indexed as

PhenotypeTransformation, GeneticAmyotrophic Lateral SclerosisAnimalsAstrocytesCells, CulturedCoculture TechniquesDisease Models, AnimalHumansInflammationMiceMice, Inbred C57BLMice, Neurologic MutantsMice, TransgenicMicrogliaMotor NeuronsSOD1 G93A proteinSuperoxide Dismutase

Identifiers

PMID22735487
PMCPMC4126417
OpenAlexW1987138690

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.